Compared with statins/ezetimibe, PCSK9 inhibitors exhibited a lower reporting probability of adverse events associated with “nervous system disorders”, “psychiatric disorders” and “metabolism and nutrition disorders”, but mixed results for musculoskeletal disorders. This evidence concerns the gene PCSK9 and psychiatric disorder.